PICCOLO: A phase 2, single arm study of mirvetuximab soravtansine in recurrent, platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor alpha (FRα) expression

Angeles Alvarez Secord1, Sharyn Lewin2, Patricia Braly3, Ying Zhuo4, Bradley Corr5, Leslie Bradford6, Arantzuza Barquin7, Erika Hamilton8, Emily Whitman9, Stephanie Henry10, Maria Jesus Rubio11, Michael Teneriello12, Christine Lee13, Robert Marsh14, Andres Redondo15, Gary Richardson16, Antonio Gonzalez-Martin17, Jizhou Wang18, Jayita Sen18, Michael Method18, Conleth Murphy19

1 Duke Cancer Institute, Durham, NC, 2 Holy Name Medical Center, Teaneck, NJ, 3 Women’s Cancer Care, Covington, LA, 4 Kadlec Clinic Hematology and Oncology, Kennewick, WA, 5 University of Colorado, Aurora, CO, 6 Maine Medical Partners, Scarborough, ME, 7 Hospital de San Chinnaro-Clara Campal, Madrid, Spain, 8 Tennessee Oncology, Nashville, TN, 9 Zangmeister Cancer Center, Columbus, OH, 10 CHU UCL Namur, Namur, Belgium, 11 Hospital Reina Sofia, Cordoba, Spain, 12 Texas Oncology-South Austin, Austin, TX, 13 Texas Oncology-The Woodlands, The Woodlands, TX, 14 Virginia Cancer Specialists, Gainesville, VA, 15 Hospital Universitario La Paz, Madrid, Spain, 16 Cabrini Hospital Malvern, Malvern, Australia, 17 Clinica Universidad de Navarra, Madrid, Spain, 18 ImmunoGen, Inc., Waltham, MA, 19 Bon Secours Health System, Cork, Ireland

BACKGROUND

- Despite advances with PARP inhibitors and anti-angiogenic agents in newly diagnosed ovarian cancer, unmet need remains for additional active and well-tolerated therapies in recurrent ovarian cancer
- Ovarian cancer overexpresses folate receptor alpha (FRα) with little to no expression in normal tissue; this tumor-specific expression provides an attractive candidate for targeted therapeutic approaches
- Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent that has shown consistent and meaningful single-agent clinical activity, along with favorable tolerability, in patients with FRα-expressing ovarian cancer
- There is no generally accepted standard of care with a clear efficacy benchmark based on prospective trials in third-line or later patients with platinum-sensitive ovarian cancer (PSOC)
- MIRV has encouraging activity as a monotherapy in platinum-resistant ovarian cancer (PROC)
- MIRV is internalized via endocytosis
- MIRV is degraded within the lysosome to release its cytotoxic payload (DM4)
- DM4, a second-generation maytansine derivative disrupts tubulin resulting in mitotic arrest and apoptosis
- DM4 also diffuses through the cell membrane allowing bystander killing of adjacent tumor cells

MECHANISM OF ACTION

The antibody portion of MIRV binds to FRα-receptor on the surface of epithelial ovarian cancer cells and has been engineered to minimize its immunogenicity

MIRV is internalized via endocytosis

DM4, a second-generation maytansine derivative disrupts tubulin resulting in mitotic arrest and apoptosis

DM4 also diffuses through the cell membrane allowing bystander killing of adjacent tumor cells

TRIAL SCHEMA

Enrollment and Key Eligibility

- Platinum-sensitive disease (PII = 6 mo)
- At least 2 prior lines of platinum-based therapy
- Patients with documented platinum allergy require only 1 prior line of platinum
- FRα-high by IHC scoring (≥75% PS2+), OR for single agent therapy as next line of therapy as determined by investigator

Statistical Assumptions

- N=75
- Null hypothesis: ORR is ≤28% tested using an optimal Simon’s two-stage design w/o pause in enrollment

Key Inclusion Criteria:

- Known BRCA status with prior PARPi required if BRCA mutation positive
- Patients may have received a non-platinum based line of therapy
- Progressed on or after most recent line of therapy
- At least one lesion that meets the definition of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
- Tumor demonstrated FRα-high membrane staining with IHC PS2 scoring ≥27% of cells staining positive with 5+ staining intensity
- Prior bevacizumab allowed

Key Exclusion Criteria:

- Endometrioid, clear cell, mucinous, or serous/salivary histology, mixed tumors containing any of those histologies or low grade/borderline ovarian cancer

Evaluation:

- Objective response rate will be evaluated by the Investigator using RECIST v1.1
- Censored survival time will be evaluated using Kaplan-Meier
- DM4 body weight (calculated using adjusted ideal body weight) intravenously once every 3 weeks

TRIAL ENDPOINTS

Primary Objective:

- To determine efficacy of MIRV in patients with recurrent PSOC and high FRα expression
- To determine the durability of response to MIRV in patients with PSOC
- To evaluate safety and tolerability of MIRV
- To characterize the clinical activity of MIRV in patients with PSOC and high FRα expression

Secondary Objectives

- ORR, which includes confirmed best response of CR or PR as assessed by the investigator
- OS defined as the time from first dose of MIRV until the date of death
- PFS defined as time from first dose of MIRV until the date of death
- OS, ORR, DOR, and PFS by blinded independent central review will be summarized as sensitivity analysis

FUTURE DIRECTIONS FOR RESEARCH

To characterize the clinical activity of MIRV in patients with PSOC and high FRα expression

REFERENCES